Wall Street is positive on Bio-Rad Laboratories, Inc. Class A Common Stock (BIO). On average, analysts give the stock a Strong Buy rating. The average price target is $876.666, which means analysts expect the stock to add by 17.39% over the next twelve months. That average ranking earns the stock an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BIO a Strong Buy today. Find out what this means to you and get the rest of the rankings on BIO!